AS703569 and Gemcitabine Combination in Advanced Malignancies

Inclusion Criteria

• •Histologically/cytologically confirmed diagnosis of measurable or assessable malignancy, who meets one of the following conditions:
• •Subject with a tumour for which gemcitabine is approved, Subject with a tumour for which gemcitabine is considered standard of care, Subject with other tumour type either refractory or intolerant to or for whom there is not an accepted standard treatment.
• •Male or female with at least 18 years of age. Life expectancy of at least 3 months.
• •Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2.
• •No more than 3 prior chemotherapy regimens for advanced/metastatic disease.
• •At least 4 weeks since last chemotherapy, hormonal therapy, immunotherapy, biological or any other pharmacological or investigational treatment or radiotherapy (6 weeks wash-out for nitrosoureas and mitomycin C, 5 half-lives for non-cytotoxics). Subjects on chronic hormonal therapy may continue with the same treatment unchanged.
• •Adequate renal, hepatic and bone marrow functions (assessed 7 days before inclusion in the trial) as defined by:
• •Serum creatinine